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ABSTRACT  
A simple, accurate, precise, selective and detectable Colorimetric method was developed for estimation of Lidocaine in five different 
Pharmaceutical Formulations. The method is an azo C-coupling reaction where Lidocaine undergoes series of reaction and finally couples with 
resorcinol to form yellow color azo compound. The colored complex was measured at 430 nm. Beers law was obeyed in concentration range of 
0.05-0.8 ug/ml. The method was validated and was found to be accurate, precise and robust with limit of detection and quantification to be 
0.014 and 0.045 ug/ml. The Color kit was also developed for On-Spot detection of Lidocaine. Measurement uncertainty principles were also 
adopted to obtain reliable results where the process of uncertainty started from specifying measurand, then identifying uncertainty sources by 
cause-effect diagram, quantification of these sources of uncertainty and then finally calculating combined standard uncertainty and expanded 
uncertainty. In the present experiment, Concentration of sample and mass of sample was the major contributor towards uncertainty for all five 
Formulations. From the five formulations combined standard uncertainty of Transdermal patch was high, followed by Aerosol, Ointment, Gel 
and Injection. 
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INTRODUCTION 
Lidocaine (LID) is chemically acetamide, 2-(diethylamino)-N-
(2,6-dimethylphenyl)-;2-(Diethylamino)-2,6-acetoxylidide. It 
acts as local anesthetics by interfering with the propagation 
of peripheral nerve impulses by blocking the sensation of 
pain. LID is, also employed in spinal anesthesia and as an 
antiarrhythmic drug. [1] 
 
Depending on the type of aromatic chain, local anesthetic can 
be divided into two main classes: amide (e.g., articaine, 
bupivacaine, lidocaine, & ropivacaine) and ester (e.g., 
benzocaine, cocaine, proparacaine, & tetracaine). Compared 
to ester anesthetics, amide local anesthetics are more 
commonly used in clinics because of relatively lower allergic 
reactions of human associated to amide local anesthetics. 
Apart from that, amide local anesthetics have better lipid 
solubility, higher potency and longer duration of action than 
the ester type.[1] The structure of Lidocaine is given in Figure 
1 
Various analytical methods are available in the literature for 
estimation of LID in  biological and pharmaceutical samples 
which includes GC[2,3], Spectrophotometric determination of 
Lidocaine in pharmaceuticals [4], with bromocresol purple[5], 
bromocresol green[6] , sodium nitroprusside[7], Methylene 
Blue[8].  
 No method is reported in the literature for estimation of LID 
by using resorcinol as the coupling reagent. Hence, it is 
proposed to use resorcinol as coupling reagent for the 
estimation of the lidocaine by Spectrophotometry.  The 
method is simple, rapid, reproducible, precise, and needs no 
extraction or heating, colour development is instantaneous, 
and the color is stable for more than 24 hours. Further, the 
controlling of experimental conditions is minimum [9]. The 
Figure 1: Structure of Lidocaine 
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method was also validated according to current ICH 
guidelines[10] 
Also application of uncertainty principles to this developed 
Colorimetry was performed. 
Measurement uncertainty [11,12,13,14] 
Analysis results are affected by random errors whose 
magnitudes depend on the measurement conditions. In order 
to determine these error sizes, measurement uncertainty of 
the analysis must be expressed together with the measured 
value, thus providing the result as a range of values with an 
accepted level of confidence. Measurement uncertainty is 
defined as a non-negative parameter characterizing the 
dispersion of the quantity values being attributed to a 
measurand, based on the information used.[11] for the 
uncertainty estimation, the steps involved start with 
measurand Specification and end with expanded uncertainty 
(EU) calculation.[12] Thus ,the current study aims to adopt a 
simple methodology for quantification of uncertainty 
components and Combined Standard Uncertainty is 
Presented by assessing these computations for colorimetric 
measurement of Lidocaine in its different pharmaceutical 
formulation.[12,13] 
MATERIALS AND METHODS 
Gift samples of standard Active Pharmaceutical Ingredient- 
Lidocaine were provided by SIDMAK LABORATORIES 
(INDIA) PVT.LIMITED.  All chemicals used in the present 
study were of analytical grade. The pharmaceutical samples 
used in the present study include Lidocaine 5% ointment, 
lignocaine hydrochloride injection 2%, Lidocaine spray 
10%w/w, Lidocaine hydrochloride gel 2%, Lidocaine patch 
5%. 
Instrumentation 
Shimadzu UV-1700 double beam spectrophotometer 
connected to a computer loaded with Shimadzu UV-Probe 
2.10 software was used for all the spectrophotometric 
measurements. The absorbance spectra of the reference and 
test solutions were carried out in 1cm quartz cells over the 
range of 200-800 nm. The samples were weighed on 
electronic analytical balance (A×120, Shimadzu). 
Reagents 
LID stock solution (500ug/ml)  
5 mg of drug was dissolved in 10 ml methanol as LID is 
practically insoluble in water. A series of standard solutions 
from stock were prepared by a suitable dilution of stock 
standard solution with distilled water to get final 
concentration of 10 ug/ml. 
HCl (0.4%w/v): 0.4 ml of concentrated hydrochloric acid was 
measured out and made upto 100 ml with distill water. 
NaNO3 (0.1%w/v): 0.1g of sodium nitrate was dissolved in 
100ml of distill water. 
NaOH (2.5%w/v): 2.5 g of sodium hydroxide was dissolved 
in 100 ml of distill water. 
Resorcinol (0.5%w/v): 0.5g of resorcinol was dissolved in 
100 ml distill water. 
Preliminary Tests 
10 ug/ml was prepared by serial dilution of standard stock 
solution. Aliquots ranging from 0.05-0.8ug/ml were 
transferred into series of 10 ml volumetric flask. To each 
flask 0.5ml HCl(0.5%w/v),1ml of NaNO3 (0.1%w/v), 
NaOH(2%W/V) and 0.5 ml Resorcinol (0.5%w/v) was added. 
The volumes was made up to mark with distil water. The 
absorbance of yellow chromogen was measured at 430nm 
against reagent blank which was prepared in similar manner 
without LID. 
Optimum Conditions 
 To achieve the optimum conditions for this method, the 
following parameters were studied. 
1) Effect of Concentration of HCl 
Various concentration of HCl was optimized. It was observed 
that the maximum color intensity and highest absorbance 
values were recorded in 0.4%w/v of HCl shown in Figure 2 
 
 
Figure 2: Optimization of Concentration of HCl 
 
2) Effect of HCl volume(ml) 
The effect of different volumes of HCl to obtain maximum 
sensitivity was investigated. The volume of the HCl required 
to obtain maximum absorption was 0.5 mL, as shown in 
Figure 3 
 
Figure 3: Optimization of ML of HCl added 
 
3) Effect of Concentration of sodium nitrite 
Various concentration of sodium nitrite was optimized. It 
was observed that the maximum color intensity and highest 
absorbance values were recorded in 0.1%w/v of sodium 
nitrite. The results are shown in Figure 4 
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Figure 4: Optimization of Concentration of Sodium 
Nitrite 
4) Effect of sodium nitrite Volume (ml)  
The effect of different volumes of NaNO3 to obtain maximum 
sensitivity was investigated. The volume of the NaNO3 
required to obtain maximum absorption was 1 mL, as shown 
in Figure 5 
 
Figure 5: Optimization of ML of Sodium Nitrite Added 
5) Effect of Concentration of sodium hydroxide 
Various concentration of NaOH was optimized and it was 
found out that maximum absorbance was found at 2.5%w/v, 
as shown in Figure 6 
 
Figure 6: Optimization of Concentration of NaOH 
 
6) Effect of sodium hydroxide Volume (ml) 
The effect of different volumes of NaOH to obtain maximum 
sensitivity was investigated. The volume of the NaOH 
required to obtain maximum absorption was 1 ml, as shown 
in Figure 7 
 
Figure 7: Optimization of ML of NaOH added 
7) Effect of Concentration of Resorcinol  
Various concentration of resorcinol was investigated and it 
was found out that maximum color intensity was found at 
0.5%w/v of resorcinol, as shown in Figure 8 
 
Figure 8: Optimization of Concentration of Resorcinol 
8) Effect of Resorcinol Volume (ml)  
The effect of different volumes of Resorcinol to obtain 
maximum sensitivity was investigated. The volume of the 
Resorcinol required to obtain maximum absorption was 1 
ml, as shown in Figure 9 
 
Figure 9: Optimization of ML of Resorcinol Added 
Recommended Procedure 
From standard stock solution (500ug/ml) of LID, series of 
dilutions was done to obtain 10ug/ml of LID. Aliquots 
ranging from 0.05-0.8ug/ml were transferred into series of 
10 ml volumetric flask. To each flask 0.5ml HCl (0.4%w/v), 
1ml of NaNO3 (0.1%w/v), 1 ml of NaOH (2.5%w/v) and 1ml 
of Resorcinol (0.5%w/v) was added. The volumes were 
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made up to mark with distill water. The absorbance of the 
yellow colored chromogen was measured at 430 nm against 
reagent blank which was prepared in the similar manner 
without LID. 
Reaction mechanism 
LID is an amide local anesthetic where it is hypothesized that 
it is an azo C-coupling reaction were Lidocaine reacts with 
water to form 2,6 Dimethyl Xylidine which reacts with 
nitrous acid formed insitu by reaction of sodium nitrite and 
hydrochloric acid to form benzene diazonium chloride. This 
undergoes coupling reaction with resorcinol using sodium 
hydroxide as catalyst to form yellow color azo compound. 
Thus the intensity of color formed is directly proportional to 
amount of LID present. 
RESULT AND DISCUSSION  
Validation Parameters for the Proposed Method[10] 
1) Linearity 
For preparing calibration graph of LID, spectra of calibration 
standards (0.05-0.8ug/ml) were recorded in the range of 200 
to 800, under the optimum experimental conditions and the 
absorbance vs. concentration plot was found to be a linear 
plot as shown in Fig 10 
 
 
Figure 10: UV Spectrum Showing Linearity of the Proposed Colorimetric Method 
 
 
Figure 11: Linearity Graph of Lidocaine 
Table 1: Statistical data for the regression equation of the 
proposed method 
PARAMETERS VALUE 
  Analytical wavelength(nm) 430 
Linearity range (ug/ml) 0.05-0.8 
Regression equation Y=0.997x+0.026 
Correlation co-efficient(R2) 0.998 
Slope 0.997 
Intercept 0.026 
Detection limit (ug/ml) 0.014 
Quantification limit (ug/ml) 0.045 
Precision 
Reproducibility of methods was checked by performing 
intra-day precision (three times a day) and inter-day 
precision (repeated triplicates for three consecutive days). 
Results are expressed in terms of standard deviation and 
%Relative standard Deviation (%RSD) as shown in Table 2. It 
can be observed that the %RSD was less than 2 for the 
proposed methods.  
 
Table 2: Precision Data of Lidocaine 
 SD %RSD 
Intraday precision 0.002082 1.469 
Interday precision 0.001528 1.088 
 
Accuracy 
To check the Accuracy of the proposed methods, Recovery 
studies were carried out at three deferent level of standard 
addition 80%, 100% and 120%. Results of Recovery studies 
are shown in Table 3.  %Recovery was the average of three 
determinations at each standard addition level. %Recovery 
for the proposed methods was found to be between 95-
105% which proves that the method was accurate.
 
Table 3: Accuracy Data of Lidocaine 
% spiking Conc 
actual(ug/ml) 
Conc 
added(ug/ml) 
Conc 
recover(ug/ml) 
% Recovery ± SD*  
80 0.1 0.08 0.083 103.7±0.00577 
100 0.1 0.1 0.099 99±0.0022 
120 0.1 0.12 0.119 99.16±0.0152 
* Average ± SD of (n= 3) experiment 
y = 0.9977x + 0.0263 
R² = 0.9986 
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Robustness  
Robustness was performed by deliberately changing method 
parameters (wavelength ±2nm) to find out indication of its 
reliability during normal usage. [10] 
Table no 4: Robustness Data of Lidocaine 
S.N. FACTOR 
Wavelength (±2nm) 
SD %RSD 
1 428 
430 
432 
0.0015 1.08 
 
Ruggedness  
Ruggedness studies were performed by altering analyst and 
instrument to find out ability of analytical method to remain 
unaffected by small variations in method parameters. [10] 
Table 5: Ruggedness Data of Lidocaine 
Sr.no Parameters SD %RSD 
 
1 
 
2 
 
Analyst  
1 0.0005 0.41 
 2 
 
Instrument 
UV1700 0.002 1.49 
UV1800 
  
Applicability of proposed method  
The proposed method was applied for quantification of five 
different marketed formulations. The formulation extraction 
process is mentioned below. Base concentration selected 
was 0.1ug/ml 
1) Aerosol, Ointment, Gel 
An amount equivalent to 5mg (Two sprays for Aerosol) was 
taken and dissolved in 10 ml of methanol to get 500ug/ml of 
stock concentration. 
 The solution was sonicated for 5-10 min and then filtered 
through 0.22um syringe filter. Further it was diluted 
according to dilution scheme followed in the proposed 
method and colorimetric estimation was performed.  
2) Lidocaine patch 5% 
An amount equivalent to 5 mg(0.1g) was taken in 10 ml of 
Dipotassium  monohydrogen  phosphate  buffer 10 mM of ph 
7.2 and was magnetically stirred for 2 hours. The solution 
was then sonicated for 15 minutes and was then filtered 
through whatman filter paper. Further it was diluted 
according to dilution scheme followed in the proposed 
method and colorimetric estimation was performed. The 
results of the assay are given in table 6 
 
Table 6: Assay Results of Formulations 
Sr.no Marketed formulations of LID Taken (mg) Recovered(mg) % Recovery 
1 Ointment (5%) 5 5.15 103 
2 Aerosol (10%) 5 5.065 101.3 
3 Gel (2%) 5 5.1 102 
4 Injection 5 4.96 99.29 
5 Patch (5%) 5 4.75 95 
 
 
A Cost Effective Color Kit For On Spot Determination Of 
Lidocaine From Formulation Was Designed. 
The kit contains 4 bottle of reagents with the brochure 
mentioning the procedure to be followed along with color 
card which shows quantification relationship between 
intensity of color formed and amount of LID present. Thus 
using this color kit u doesn’t need to have UV 
spectrophotometer every time to quantify Lidocaine. 
Recommended Procedure for Color Kit 
This color kit can detect Lidocaine present in very minute 
amount (0.05-0.8ug/ml) which makes this colorimetric 
technique highly specific method for On-Spot determination.  
The sample containing Lidocaine was transferred into 10 ml 
volumetric flask. To each flask 10 drops of Hcl (bottle no 1), 
15 drops of sodium nitrite (bottle no 2), 15 drops of sodium 
hydroxide(bottle no 3) and  10 drops of resorcinol (bottle no 
4) was added. The volumes were made up to mark with 
distill water (bottle no 5). The intensity of yellow color was 
used for quantification of Lidocaine using color card.
 
 
Figure 12: Color Card to Quantify Lidocaine from Range (0.05-0.8 ug/ml) 
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Estimation of measurement uncertainty [12,13,14] 
Identification and quantification of different uncertainty 
parameters 
Although the method was validated, still there were some 
doubts in the results, as few factors were not included in the 
validation such as errors during mass of sample taken etc. So 
Uncertainty estimation was carried out starting with the 
identification of sources of uncertainty and compiled up with 
the Combined Standard Uncertainty and Expanded 
Uncertainty results.[12,13] 
Identification of sources of uncertainty 
Construction of the cause and effect diagram 
In order to list uncertainty sources, it is very convenient to 
use the cause and effect diagram because it shows how the 
sources link to each other and indicate their influence on the 
result. 
So a cause and effect diagram was constructed as shown in 
Fig. 13, which points out the different sources which may 
affect the sample analysis measurement. These parameters 
are: 
Uncertainty associated with standard and test solution 
preparation V, uncertainty due to Concentration of analyte C, 
uncertainty associated with sample mass measurement 
Msample, uncertainty due to Recovery of method R and 
Precision of method P. These all parameters contribute to the 
overall uncertainty in final analytical results in marketed 
formulations. This diagram will also help in resolving any 
repeatability of components in uncertainty. These 
parameters are shown in Eq.(1) 
Lidocaine sample = C* V* 10 -3 / M sample R    (1) 
Where, Lidocaine sample, Lidocaine quantity (mol/kg); C, 
Lidocaine concentration in 10 mL 
Volumetric flask (M); V, volume of 10 mL volumetric flask 
(mL); Msample, Lidocaine sample 
Mass taken (kg); R, Recovery of method. 
Now after identification, these sources were quantified and 
their individual effect on overall 
Uncertainty was studied and compiled up in the form of CSU 
and EU by carefully choosing Coverage factor.[12,13] 
 
 
Figure 13: Cause-Effect Diagram 
Effect of individual parameters on measurement 
uncertainty i.e Quantify uncertainty components 
1) Uncertainty associated with standard and test 
solution preparation, (V) 
The effect on volume of 1 mL pipette and 10 mL volumetric 
flask is mainly influenced by the three parameters i.e. 
calibration of the volumetric flask and pipette (at the time of 
manufacturing), repeatability and temperature.  
1.1) Effect of volume of 10 mL volumetric flask - 
calibration of 10 ml volumetric flask  
u (v cal) 
 Deviation of value from nominal volume for 10 mL 
volumetric flask  was ± 0.009 mL (at 27°C) 
 by assuming that standard deviation is not claimed by 
Manufacturer with confidence interval limit, standard value 
of uncertainty can be calculated with triangular distribution. 
Thus, uncertainty associated with liberation of 10 mL 
volume of 10 mL  volumetric flask due to calibration u (Vcal) 
is shown in Eq.(2) 
u (V10-cal)= 
  
√ 
     =
      
√ 
  = 0.0036 mL    (2) 
1.2)  Repeatability u (Vrep) 
After filling and weighing of 10 mL volumetric flask, 
standard uncertainty of volumetric flask 
was established at 0.0014 mL. 
1.3) Temperature u (Vtemp)  
The manufacturer has calibrated volumetric flask at the time 
of manufacturing at a temperature 
of 27°C, while temperature in the laboratory varied within a 
range of Δt = ± 4°C. This 
difference was overcome by calculating uncertainty value 
with estimation of temperature range 
and volume dilatation coefficient. Volume expansion of 
liquid was taken into consideration, as it 
is quite higher than expansion of volumetric flask. The 
volume expansion coefficient, γ, of water 
is 2.1×10-4 /°C. Thus uncertainty for 10 mL volumetric flask 
ΔV10 was calculated by Eq. (3) 
ΔV10 =V10 ×γ× Δt   (3) 
Gandhi et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2020; 10(2):86-96 
ISSN: 2250-1177                                                                                  [92]                                                                                 CODEN (USA): JDDTAO 
Where Δ V10, uncertainty of the 10 mL volumetric flask; 
V10, volume of the 10 mL volumetric 
flask; γ, volume dilatation coefficient; Δt, temperature 
variation in the laboratory. Thus, we obtain that uncertainty 
for volumetric flask of 10 mL is 0.0084 mL, also assuming 
temperature variation is rectangular distribution, standard 
uncertainty for 10 mL volumetric flask 
due to the temperature effect will be u (V10-temp) as shown in 
Eq. (4). 
u (V10-temp) = 
              
√ 
   = 0.0048 mL   (4) 
Thus, standard uncertainty due to liberation of 10 mL 
volume of 10 mL volumetric flask was 
calculated according to Eq. (5) and was found to be 0.0108 
mL. Standard relative uncertainty 
was calculated and shown in Eq. (6). 
u (V10) = √           ))
     (        ))
               ))
   (5) 
u (V10) = 0.0108 mL 
The standard relative uncertainty will be: 
     )
   
          mL   (6) 
Similarly the standard relative uncertainty due to volume of 
1 mL pipette was found to be 0.00338 mL 
Thus the standard uncertainty due to discharge of volume 
for 1 ml pipette and 10 ml volumetric flask was found to be 
4.4 ×10-2  ml and standard relative uncertainty was found to 
be 4.9×10-3 ml 
2) Uncertainty associated with the sample mass 
measurement (Msample) 
Estimation of sample mass has three types of uncertainty 
sources such as sensitivity, linearity, and repeatability. Mass 
of the sample was expressed in kg for convenient 
traceability of results. 
2.1) sensitivity 
The range of difference in weighed mass was very less and 
the same weighing balance was used each time. Therefore, 
uncertainty due to sensitivity of balance can be neglected. 
2.2) linearity 
As the manufacturer data indicated linearity value is 
0.0001g thus, to determine overall 
Uncertainty value, standard uncertainty due to linearity was 
considered. A rectangular distribution was assumed to 
convert contribution of linearity. It was calculated and is 
expressed in Eq (7)  
u = 
            
√ 
   = 5.77 ×10-8 kg    (7) 
2.3) Repeatability  
Uncertainty due to repeatability was calculated for ointment, 
gel, aerosol, injection, transdermal patch by weighing the 
formulation 10 times and taking into account standard 
deviation. 
2.4) Calculation of relative standard uncertainty due to 
sample mass 
The standard uncertainty due to sample mass is calculated 
by Eq (8) 
u (M sample) = √     )     )     (8) 
 
Standard uncertainty for ointment, gel, injection, aerosol, 
transdermal patch was found to be 1.42×10-7 , 1.35×10-7 
,1.02×10-7, 2.08×10-7 , 1.60×10-7. 
From standard uncertainty relative standard uncertainty for 
ointment, gel, injection, aerosol, transdermal patch was 
found to be 2.7×10-2, 2.6×10-2 , 2.0×10-2, 4.1×10-2 , 3.3×10-2. 
3) Uncertainty due to Concentration (C) 
Uncertainty due to concentration for Lidocaine 5 different 
formulation was expressed as concentration uncertainty 
from calibration curve and is given by Eq (9) 
U (C) = 
  
 
√ 
 
 
 
 
 
       )
   
 
  (9) 
Where 
Sr = √∑
          ) 
   
 
    
Sxx =∑         
 
   )
  
Sr, residual standard deviation 
n, number of measurements used for calibration curve 
(n=18)  
p, number of measurements used to obtain concentration of 
the sample;  
c, lidocaine concentration in sample (M) 
cavg average of standard solution (M) 
Yj, analytical signal of the measurement;  
j, index for number of measurements made in order to 
obtain the calibration curve; 
i, index for number of solution for calibration; b, slope of 
calibration curve (L/mol); a, calibration curve intercept 
The sample solution was measured ten times (p = 10) and 
concentration was obtained from the calibration curve 
regression equation Eq (10) 
y= mx+c   (10) 
Where Y, absorbance of sample; c, calibration curve 
intercept; m, calibration curve slope; x, 
Concentration of Lidocaine.  
For the determination of calibration curve, six solutions have 
been measured three times (n=18). The sample solution was 
measured ten times, and the analyte concentration 
(Lidocaine) from ointment, gel, injection, aerosol, 
transdermal patch was measured by using Eq 9. 
Also relative standard uncertainty was calculated whose 
results are shown in table no 7  
4) Uncertainty due to Precision, P 
Precision is divided into repeatability, intermediate 
precision, and reproducibility. Repeatability expresses the 
precision under same operating conditions over a short 
period of time. Whereas intermediate precision expresses 
within-laboratories variations: different days, different 
analysts, and different equipment. And Reproducibility 
expresses the precision between laboratories. 
Here three different analysts were chosen to perform the 
precision uncertainty study shown in table 7 
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Table 7:  Precision Uncertainty Measurement Data of Three Analysts 
No of measurement, N Analyst 1 Analyst 2 Analyst 3 
1 0.101 0.102 0.099 
2 0.098 0.094 0.105 
3 0.105 0.098 0.104 
4 0.098 0.102 0.098 
5 0.1 0.099 0.099 
6 0.102 0.1 0.102 
7 0.104 0.101 0.104 
8 0.098 0.105 0.101 
9 0.105 0.102 0.102 
10 0.101 0.101 0.1 
Where the uncertainty due to precision was calculated from data obtained from intermediate precision measurement results of 
three analysts. One-way ANOVA test was also performed to evaluate the closeness of measurement results between three 
analysts whose results are shown in table 8 
Table 8: Results Showing One-Way ANOVA Test 
Source of 
variation 
Sum of 
square 
Degree of 
freedom 
Mean square F- value 
calculated 
F-value 
tabulated 
Between 
analyst 
0.0000056 2 0.0000028  
     0.37 
    
     3.25 
Within 
treatment 
0.0002004 27 0.0000074 
Result F tab > F cal 
Conclusion No significant difference between analyst 
 
 
Uncertainty due to precision is calculated by equation (11)10 
P = 
  
   √ 
       (11) 
Where S.D = standard deviation of the analysts 
Avg = average result of analyst with maximum deviation 
N = Number of measurement made by analyst  
Results for uncertainty due to precision for ointment, gel, 
injection, aerosol, transdermal patch is given in table no 9 
5) Uncertainty due to Recovery of Method 
Recovery (or bias) is a measure of the losses or interferences 
that arise from the difference between the amounts of 
analyze measured in the sample relative to that expected in 
the sample which gives an uncertainty that needs to be 
calculated [10].  Results of recovery are evaluated as 
percentage recovery from sample matrix of representative 
spiking. The value of recovery was obtained from validation 
of method as discussed earlier. 
When a ‘spike’ is used to estimate recovery, the recovery of 
analyte from the sample may differ 
from recovery of spike so that an uncertainty needs to be 
evaluated. So for all the formulations uncertainty associated 
with recovery of method was evaluated using Eq. (10) and 
recovery was simply calculated by Eq. (11). 
Rm = 
            
      
          (10) 
Where Cobs: mean of replicate analysis of spiked sample 
 Cspike:  nominal concentration of Lidocaine in spiked 
sample 
Cnative : observed concentration of analyte in the unspiked 
sample. 
U(R) = Rm × √
    
 
         
 
              ) 
  
 (       )
      
)        (11) 
Where Sobs = standard deviation of results from replicate 
analysis of spiked samples 
N= number of replicates 
U (Cspike) = standard uncertainty in concentration of spiked 
samples. It can be calculated by using  Equation (12) 
U (Cspike) = Cspike × √
       )
     )
 
 
 
   )
  ) 
 
         (12) 
U (Cspike) was calculated using uncertainty due to mass of 
Lidocaine (from balance), calibration of pipette, calibration 
of flask and temperature effect. Thus the combined 
uncertainty due to recovery of method, calculated by 
equation (11) for ointment, gel, injection, aerosol, 
transdermal system is given in table no 9 
 
Gandhi et al                                                                                                                Journal of Drug Delivery & Therapeutics. 2020; 10(2):86-96 
ISSN: 2250-1177                                                                                  [94]                                                                                 CODEN (USA): JDDTAO 
Table 9: Summary of all the parameters having impact on Lidocaine determination from its Formulations. 
Parameters Volume, 
 V (ml) 
Concentration,  
C (M) 
Mass of sample, (Kg) Recovery Precision 
Ointment  
Value 10 4.39x10-10  5.15x10-6  103x10-2   
Std uncertainty 4.4x10 -2  1.706x10-11  1.42x10-7  3.45x10-3  5.0x10-3  
Relative std uncertainty 4.9x10-3  3.8x10-2  2.7x10-2  3.33x10-3  5.0x10-3  
Gel  
Value 10 4.35x10-10  5.1x10-6  102x10-2   
Std uncertainty 4.4x10 -2  1.493x10 -11  1.35x10-7  2.9x10-3  5.2x10-3  
Relative std uncertainty 4.9x10-3  3.4x10-2  2.6x10-2  2.8x10-3  5.2x10-3  
Injection  
Value 10 4.224x10-10  4.96x10-6  99.29x10-2   
Std uncertainty 4.4x10 -2  1.237x10-11  1.02x10-7  1.16x10-3  4.0x10-3  
Relative std uncertainty 4.9x10-3  2.9x10-2  2.0x10-2  1.10x10-3  4.0x10-3  
Aerosol  
Value 10 4.309x10-10  5.065x10-6  101.3x10-2   
Std uncertainty 4.4x10 -2  1.408x10-11  2.08x10-7  3.6x10-3  5.0x10-3  
Relative std uncertainty 4.9x10-3  3.2x10-2  4.1x10-2  3.5x10-3  5.0x10-3  
Transdermal patch  
Value 10 4.055x10-10  4.75x10-6  95x10-2   
Std uncertainty 4.4x10 -2  1.65x10 -11  1.60x10-7  3.79x10-4  6.0x10-3  
Relative std uncertainty 4.9x10-3  4.0x10-2  3.3x10-2  3.9x10-3  6.0x10-3  
 
 
 
Figure 14: Graph Showing Contributions of Various 
Parameters towards Uncertainty of Ointment 
 
 
Figure 15: Graph Showing Contributions of Various 
Parameters towards Uncertainty of Gel 
 
 
Figure 16: Graph Showing Contributions of Various 
Parameters towards Uncertainty of Injection 
 
 
Figure 17: Graph Showing Contributions of Various 
Parameters towards Uncertainty of Aerosol
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Figure 18: Graph Showing Contributions of Various 
Parameters towards Uncertainty of Transdermal patch 
 
6) Combined Standard Uncertainty (CSU) 
Following the estimation of individual or groups of 
components of uncertainty and expressing them as standard 
uncertainties, the next stage is to calculate the combined 
standard uncertainty [12, 13]. 
For determining the CSU of the measurement result, 
individual standard uncertainties were combined using the 
usual “root-sum-of-squares” method12 shown in Equation 
(13) 
The values of all the parameters having impact on Lidocaine 
determination from its formulation is complied in table no 7. 
Further these values using equation (1) were used to 
quantify Lidocaine from Ointment, Gel, Injection, Aerosol, 
Transdermal patch and thus, we obtain quantity of 8.28x10-7, 
8.32x10-7 , 8.5x10-7 , 8.39x10-7, 8.8x10-7 mol/kg  respectively.  
         )
       
 =√ 
     )
   
)   
   )
 
)   
         )
       
)   
    )
  
)   
   )
 
)    (13) 
 
7) Expanded Standard Uncertainty (EU) 
The final stage is to multiply the combined standard 
uncertainty by the chosen coverage factor (k=2) in order to 
obtain an expanded uncertainty. The expanded uncertainty is 
required to provide an interval which may be expected to 
encompass a large fraction of the distribution of values 
which could reasonably be attributed to the measurand [12, 
13]. 
Thus expanded uncertainty of Lidocaine from its different 
pharmaceutical formulations was estimated by multiplying 
the combined standard uncertainty by coverage factor, k = 2, 
at confidence level of 95%, the results were found to be as 
follows:  
EU ointment= 7.80x10-8 Mol/kg 
EU gel = 7.23x10-8 Mol/kg 
EU injection = 6.08x10-8 Mol/kg 
EU aerosol = 8.82x10-8 Mol/kg 
EU transdermal patch = 8.93x10-8 Mol/kg 
 
 
 
Figure 19 : Comparison Shown Between Combined Standard Uncertainties of Five Lidocaine Formulations 
 
CONCLUSION 
 Colorimetric method developed for estimation of Lidocaine 
in five pharmaceutical Formulations was found to be 
accurate, precise, specific which was proved from validation 
data. Color kit was developed for On-Spot detection and 
quantification of Lidocaine. The estimation of uncertainty 
components proved to be a good way for the experimental 
model to obtain contribution of the uncertainty in the 
analytical results.  In the present experiment, Concentration 
of sample and mass of sample was the major contributor 
towards uncertainty for all five Formulations which was 
proved from Figure 14-18. Also, from the five formulations 
combined standard uncertainty of Transdermal patch was 
high, followed by Aerosol, Ointment, Gel, Injection as 
depicted by Figure 19. 
Injection <  Gel < Ointment < Aerosol < Transdermal patch
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